Amylyx Formalizes $500M Upsized Offering: $471.7M Net Proceeds, Closing August 21
AMLX has more than doubled off its 52-week low of $7.82 on elevated volume (3.8× avg).
Summary
Amylyx formalized its upsized $500 million public offering, with net proceeds of $471.7 million to fund the commercial launch of avexitide after positive Phase 3 results.
Key Events · Financing and Capital Events · AMLX
-
Underwriting Agreement Executed
Amylyx entered into an underwriting agreement on August 19, 2026 with Leerink Partners, Morgan Stanley, Guggenheim Securities, and LifeSci Capital for 14,090,000 shares at $35.50 per share.
-
Net Proceeds of $471.7M
After underwriting discounts and expenses, net proceeds are approximately $471.7 million, or $542.5 million if the 2,113,500-share over-allotment option is fully exercised.
-
Upsized from $350M to $500M
The offering was upsized 43% from the initial $350 million plan announced August 18, reflecting strong investor demand following positive Phase 3 LUCIDITY results for avexitide.
-
Use of Proceeds
Proceeds will fund the potential commercial launch of avexitide in the U.S., including securing additional manufacturing capacity, plus R&D and working capital.
Analysis · AMLX · Life Sciences
Amylyx entered into an underwriting agreement for 14.09 million shares at $35.50 per share, raising approximately $471.7 million in net proceeds (or $542.5 million if the over-allotment option is fully exercised). The offering was upsized from the initial $350 million plan announced two days ago, reflecting strong demand following positive Phase 3 LUCIDITY results for avexitide. The capital funds the potential commercial launch of avexitide, including manufacturing capacity, and extends the company's cash runway. The offering is priced at a modest discount to the current stock price of $39.71, and the 45-day lock-up period for insiders signals confidence in the near-term outlook.
At the time of this filing, AMLX was trading at $39.71 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.4B. The 52-week trading range was $7.82 to $40.44. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.